Prana Biotechnology (PRAN)
It’s a slippery slope when you start placing bets based on a company with no marketable product, and a lead candidate that’s only in Phase 2 trials. But, Prana Biotechnology (PRAN) may be one of those cheap stocks within the drugmaking world that’s worth the risk.
PBT2 is a drug taking aim at Alzheimer’s, and a compelling one at that. Like most Alzheimer’s drug in development right now, a buildup of amyloid plaque in the brain is the focal point for Prana. But, Prana Biotechnology believes these beta amyloid proteins to reach toxic levels when they react with naturally-occurring zinc and copper in brain synapses.
Solution? Return those synaptic metals to neurons before they get a chance to reach amyloid proteins. Technical, yes, but the bottom line is that the results to date are encouraging.
Just bear in mind this is largely an all-or-nothing bet on the drug, though PRAN stock could rally nicely leading up to its D-Day approval.